Ocugen, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocugen, Inc. (NASDAQ: OCGN) announced on December 20, 2021, that its Compensation Committee has approved stock options and restricted stock units (RSUs) for a new employee. The stock options total 6,750 shares with an exercise price of $5.02, reflecting the closing price on the grant date of December 16, 2021. The RSUs cover 1,150 shares and both grants vest over three years. This move aligns with Nasdaq Listing Rule 5635(c)(4) as an inducement for employment, supporting Ocugen's focus on gene therapies and COVID-19 vaccine development.
- Grant of stock options and RSUs indicates commitment to incentivize new talent.
- Stock options have a competitive exercise price of $5.02.
- None.
MALVERN, Pa., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 6,750 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 1,150 shares of common stock to one newly hired team member. The stock options and RSUs were granted as of December 16, 2021, as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have a ten-year term and have an exercise price of
About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug — “one to many,” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets. For more information, please visit www.ocugen.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.
Ocugen Contact:
Ken Inchausti
Head, Investor Relations & Communications
IR@Ocugen.com
FAQ
What stock options did Ocugen, Inc. grant on December 16, 2021?
How many restricted stock units (RSUs) were granted to the new employee at Ocugen?
What is the vesting period for the stock options and RSUs at Ocugen?
Why were the stock options and RSUs granted to the new employee?
